Delving into the Latest Updates on Buraydah Private Colleges with Synapse

概览

疾病领域	数量

神经系统疾病	1

排名前五的药物类型	数量

小分子化药	1

排名前五的靶点	数量

BACE1 x GRIN x GSK-3β	1

关联

1

项与 Buraydah Private Colleges 相关的药物

F1094-0201

靶点

BACE1 x GRIN x GSK-3β

作用机制

BACE1抑制剂 [+2]

在研机构

Buraydah Private Colleges

原研机构

Buraydah Private Colleges

在研适应症

阿尔茨海默症

非在研适应症-

最高研发阶段临床前

首次获批国家/地区-

首次获批日期-

100 项与 Buraydah Private Colleges 相关的临床结果

登录后查看更多信息

0 项与 Buraydah Private Colleges 相关的专利（医药）

登录后查看更多信息

55

项与 Buraydah Private Colleges 相关的文献（医药）

2025-03-01·CNS & Neurological Disorders - Drug Targets

Recent Development of Zolmitriptan Formulation in Migraine Therapy: Production, Metabolism and Pharmaceutical Aspects

Article

作者: Al-Jarallah, Abdulrahman Mohammed ; Alqethami, Mohammed Ghanim ; Husain, Asif ; Bano, Farha ; Aba Alkhayl, Faris F. ; Dewangan, Rikeshwer Prasad ; Alsufyani, Mohammed Omair ; Rashid, Mohammad ; Hakme, Mohammed Japer Mohammed ; Alhothali, Khadijah Oudah R.

The triptans class of pharmaceuticals, which was created to treat acute migraine, is made up of indole-containing drugs that bind to a subset (1B/1D) of 5-hydroxytryptamine receptors and are agonists of serotonin receptors. At the moment, naratriptan, eletriptan, zolmitriptan, rizatriptan, almotriptan, and frovatriptan are the seven types of triptans available on the market. Among these are the FDA-approved triptans, Zolmitriptan and Sumatriptan, which are selective serotonin (5-hydroxytryptamine) agonists. Zolmitriptan, a synthetic tryptamine derivative and a well-known member of the triptan family, is available as an orally disintegrating tablet, nasal spray, and tablet. There are melt formulations of rizatriptan and zolmitriptan available on the market that are easier to use and absorb, comparable to regular pills. Recently, the FDA approved zolmitriptan, a medication with tolerability comparable to sumatriptan. Whereas zolmitriptan is only available as an oral melt or tablet, sumatriptan is available as a nasal spray, oral preparation, or self-injectable kit. The only known antimigraine drugs that were widely utilized before the triptan period were ergotamine and dihydroergotamine. However, zolmitriptan binds to plasma proteins only 25% of the time because of significant first-pass degradation. Researchers have looked into fresh ideas for solving this issue and innovations to overcome its pharmacokinetic difficulties. This article emphasizes the role of zolmitriptan in the treatment of migraines, highlighting its pharmacological properties, production, metabolism, and structural features.

2025-02-01·Ageing Research Reviews

Inflammatory signaling pathways in Alzheimer's disease: Mechanistic insights and possible therapeutic interventions

Review

作者: Abomughaid, Mosleh Mohammad ; Chauhan, Payal ; Alhindi, Abdulghani A ; Abomughaid, Mosleh Mohammad ; Gupta, Saurabh ; Avinash, D ; Sharma, Swati ; Alghamdi, Saad ; Jha, Niraj Kumar ; Lakhanpal, Sorabh ; Almutary, Abdulmajeed G. ; Begum, M Yasmin ; Singh, Govind ; Sinha, Aashna ; Iqbal, Danish ; Babalghith, Ahmad O ; Nelson, Vinod Kumar ; Jha, Niraj Kumar ; Kyada, Ashish Kumar ; Alzahrani, Hassan A ; Kumar, Sandeep ; Wadhwa, Karan ; Jyothi, S Renuka ; Imran, Mohd ; Almutary, Abdulmajeed G ; Abu-Seer, Eman Adnan ; Mishra, Prabhu Chandra ; Chaudhary, Kamlesh ; Iqbal, Danish

The complex pathophysiology of Alzheimer's disease (AD) poses challenges for the development of therapies. Recently, neuroinflammation has been identified as a key pathogenic mechanism underlying AD, while inflammation has emerged as a possible target for the management and prevention of AD. Several prior studies have demonstrated that medications modulating neuroinflammation might lessen AD symptoms, mostly by controlling neuroinflammatory signaling pathways such as the NF-κB, MAPK, NLRP3, etc, and their respective signaling cascade. Moreover, targeting these inflammatory modalities with inhibitors, natural products, and metabolites has been the subject of intensive research because of their anti-inflammatory characteristics, with many studies demonstrating noteworthy pharmacological capabilities and potential clinical applications. Therefore, targeting inflammation is considered a promising strategy for treating AD. This review comprehensively elucidates the neuroinflammatory mechanisms underlying AD progression and the beneficial effects of inhibitors, natural products, and metabolites in AD treatment.

2025-01-01·Brain Research

Cellular stress response and neuroprotection of flavonoids in neurodegenerative diseases: Clinical insights into targeted therapy and molecular signaling pathways

Review

作者: Suliman, Muath ; Hussein Sweilam, Sherouk ; Dharani Prasad, P. ; Durgawale, Trupti Pratik ; Obaidur Rab, Safia ; Alshehri, Mohammed Ali ; Usman, Md Rageeb Md ; Reddy, Konatham Teja Kumar ; Shanmugarajan, Thukani Sathanantham ; Sultana, Rokeya ; Zehravi, Mehrukh ; Emran, Talha Bin ; Varuna Naga Venkata Arjun, Uppuluri ; Paramasivam Kannan, Shruthi ; Ali Alshehri, Mohammed ; Sathanantham Shanmugarajan, Thukani ; Teja Kumar Reddy, Konatham ; Bin Emran, Talha ; Kannan, Shruthi Paramasivam ; Utpal, Biswajit Kumar ; Arjun, Uppuluri Varuna Naga Venkata ; Kumar Utpal, Biswajit ; Pratik Durgawale, Trupti ; Sweilam, Sherouk Hussein ; Rageeb Md. Usman, Md. ; Rab, Safia Obaidur ; Sutradhar, Baishakhi ; Prasad, P Dharani

Neurodegenerative diseases (NDs) are caused by the gradual decline of neuronal structure and function, which presents significant challenges in treatment. Cellular stress responses significantly impact the pathophysiology of these disorders, often exacerbating neuronal damage. Plant-derived flavonoids have demonstrated potential as neuroprotective agents due to their potent anti-inflammatory, anti-apoptotic, and antioxidant properties. This review provides an in-depth analysis of the molecular processes and clinical insights that cause the neuroprotective properties of flavonoids in NDs. By controlling essential signaling pathways such as Nrf2/ARE, MAPK, and PI3K/Akt, flavonoids can lower cellular stress and improve neuronal survival. The study discusses the challenges of implementing these discoveries in clinical practice and emphasizes the therapeutic potential of specific flavonoids and their derivatives. Flavonoids are identified as potential therapeutic agents for NDs, potentially slowing progression by regulating cellular stress and improving neuroprotection despite their potential medicinal uses and clinical challenges. The study designed a strategy to identify literature published in prestigious journals, utilizing search results from PubMed, Scopus, and WOS. We selected and investigated original studies, review articles, and research reports published until 2024. It suggests future research and therapeutic approaches to effectively utilize the neuroprotective properties of flavonoids.

100 项与 Buraydah Private Colleges 相关的药物交易

登录后查看更多信息

100 项与 Buraydah Private Colleges 相关的转化医学

登录后查看更多信息